Factors impacting on discordance with treatment plan in head and neck cancer patients: a retrospective, population-based cohort study
Authors:
- 8 June 2019
- journal article
- research article
- Published by Springer Nature in Supportive Care in Cancer
- Vol. 28 (2) , 951-958
Abstract
The aims of this study were to identify the factors and reasons impacting discordance with the treatment plan in head and neck cancer (HNC) patients and compare the differences between the concordance group and the discordance group.Keywords
Funding Information
- Chang Gung Memorial Hospital (CMRPG3J0241)
This publication has 28 references indexed in Scilit:
- Interventions for enhancing medication adherenceCochrane Database of Systematic Reviews, 2014
- Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012International Journal of Cancer, 2014
- Factors Associated with Lung Cancer Patients Refusing Treatment and Their Survival: A National Cohort Study under a Universal Health Insurance in TaiwanPLOS ONE, 2014
- Characteristics, survival, and related factors of newly diagnosed colorectal cancer patients refusing cancer treatments under a universal health insurance programBMC Cancer, 2014
- Classifying squamous cell carcinoma of the head and neck: prognosis, prediction and implications for therapyExpert Review of Anticancer Therapy, 2013
- Race and Health Disparities in Patient Refusal of Surgery for Early-Stage Non-Small Cell Lung Cancer: A SEER Cohort StudyAnnals of Surgical Oncology, 2011
- Phase III Trial of Pemetrexed Plus Best Supportive Care Compared With Best Supportive Care in Previously Treated Patients With Advanced Malignant Pleural MesotheliomaJournal of Clinical Oncology, 2008
- Perceptions and practice of concordance in nurses’ prescribing consultations: Findings from a national questionnaire survey and case studies of practice in EnglandInternational Journal of Nursing Studies, 2007
- Interventions for enhancing medication adherence2005
- The content and amount of information given by medical oncologists when telling patients with advanced cancer what their treatment options areEuropean Journal of Cancer, 2004